Stay updated on Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the number of participants enrolled in a clinical research study investigating the combination of nivolumab and ISA101 to control cancer that has spread.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:46.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' which includes examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now starts with 'Inclusion Criteria: Signed Written Informed Consent' and provides detailed requirements for study participation.
    Difference
    44%
    Check dated 2024-05-22T21:37:21.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:15:02.000Z thumbnail image

Stay in the know with updates to Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and HPV-16 Vaccine for Incurable Solid Tumors Clinical Trial page.